




PCT/GB 2004 / 001639

Rec'd PCT/PTO 26 SEP 2006

10/557464  
INVENTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 5 May 2004



**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

THE PATENT OFFICE

15 APR 2003

The  
Patent  
Office

NEWPORT

## Request for grant of a patent

*(see the notes on the back of this form. You can also get an explanatory leaflet from the Patent office to help you fill in this form)*15APR03 E8083951 D10185  
P01/7700 0.00-0308672.5

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1 Your reference

SYN 60012

2 Patent application number

*(The Patent Office will fill in this part)*

0308672.5

3 Full name, address and postcode of the or of each applicant (underline all surnames)

JOHNSON-MATTHEY PLC  
2-4 Cockspur Street, Trafalgar Square, London, SW1Y 5BQPatents ADP Number *(if you know it)*

8519803001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4 Title of the invention

Process

5 Name of Your Agent *(if you have one)*

GIBSON, Sara Hillary Margaret

*"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)*Synetix Intellectual Property Department  
PO Box 1,  
Belasis Avenue  
Billingham  
Cleveland  
England, TS23 1LBPatents ADP Number *(if you know it)*

7895139007

6 If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and *(if you know it)* the or each application numberCountry      Priority Application number  
*(if you know it)*      Date of Filing  
*(day / month / year)*

7 If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

Number of earlier application  
*(day / month / year)*

8 Is a statement of inventorship and of right to grant of a patent required in support of this request?

Yes

*Answer yes if:*

- a) any applicant named in part 3 is not an inventor; or
- b) there is an inventor who is not named as an applicant; or
- c) any named applicant is a corporate body.

*See Note (d)*

Patents Form 1/77

9 Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description	8
Claim(s)	1
Abstract	1

Drawings

*8*

*1*

*1*

*8*

10 If you are also filing any of the following state how many against each item

Priority documents

Translations of priority documents

Statement of Invention and right to grant of a patent (Patents Form 7/77)

Request for Preliminary Examination and search (Patents Form 9/77)

Request for Substantive Examination (Patents Form 10/77)

Any other documents (Please specify)

11

I/We request the grant of a patent on the basis of this application

Signature



Date

14.4.2003

12 Name and daytime telephone number of person to contact in the United Kingdom

Sara H.M. Gibson  
01642 522650

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been issued, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Process

This invention relates to a process for performing a coupling reaction between acetaldehyde and alkynes to produce hydroxyalkynes and their derivatives.

5 The asymmetric coupling reaction of aldehydes and alkynes to produce hydroxyalkynes and their derivatives is of interest to the fine chemicals industry where it provides a source of asymmetry useful in preparing chiral products such as pharmaceutical intermediates.

10 The asymmetric coupling reaction of aldehydes and alkynes is known. In particular, the preparation of chiral propargyl alcohols, such as 3-hydroxy-1-butyne, using zinc triflate in an enantioselective aldehyde addition reaction with a terminal alkyne, in the presence of triethylamine and (+)- or (-)-N-methylephedrine has been described. (See for example, Carreira et al, *Organic Letters*, 2000, 2(26), 4233-4236 and Carreira et al, *J. Am. Chem. Soc.*, 2000, 122, 1806-1807). By the term 'terminal' we mean an alkyne having a hydrogeh atom

15 bound to one carbon atom forming the carbon-carbon triple bond, i.e. a  $C\equiv C-H$  group. This reaction has been used to provide chiral propargyl alcohols, via, for example, thermally unstable alkynediols. However these workers have only considered aldehydes having 3 or more carbon atoms. Similarly, WO 02/094741 describes a process for performing coupling reactions to prepare 1,4-, 1,5- or 1,6- diols from aldehydes and hydroxyalkynes wherein the

20 aldehydes are of general formula  $R^1C(O)H$  in which  $R^1$  represents a saturated or unsaturated alkyl having between 2 and 24 carbon atoms, cycloalkyl or aryl group. Herforeto, acetaldehyde ( $CH_3CHO$ ) has presented practical challenges that have prevented its successful use in Lewis acid mediated coupling reactions such as those described above. In particular, the propensity of acetaldehyde for self-condensation to form mixed oligomeric species has

25 presented a significant obstacle. Consequently, useful acetaldehyde-derived products such as chiral alkynes and chiral 1,4-diols and their derivatives have not been successfully obtained in commercially attractive yields.

30 We have discovered a new method whereby the coupling reaction of acetaldehyde and terminal alkynes may be performed in high yield.

Accordingly this invention provides a process for performing a coupling reaction between acetaldehyde and a terminal alkyne to yield a hydroxyalkyne comprising the steps of;


35           iii) Reacting in the absence of a solvent, a terminal alkyne with a Lewis acidic metal salt in the presence of an alkanolamine ligand and a cyclic amine base to form an metal-alkyne complex, and

              (i) adding a solution of acetaldehyde to the metal-alkyne complex and allowing the mixture to react.

Acetaldehyde as commercially provided may contain small amounts of water and/or oligomeric species formed by self-condensation reactions. While such crude acetaldehyde may be used in the process of the present invention, it is preferable to purify the acetaldehyde before use, e.g. by distillation or drying using suitable molecular sieves.

5


The terminal alkyne used for preparing the hydroxyalkyne may be any alkyne having a terminal hydrogen, i.e. a C≡C-H group, for example liquid acetylene in a pressurised, sealed vessel may be used. However, a particularly useful group of terminal alkynes are those liquid alkynes that may undergo thermal fragmentation reactions. These alkynes are readily available and 10 relatively easy to handle compared to acetylene. Thus in one embodiment, the terminal alkyne is of general formula  $R^1R^2C(OH)C\equiv CH$  in which  $R^1$  and  $R^2$  may be the same or different and are selected from the group comprising methyl, ethyl and propyl. Preferably  $R^1$  and  $R^2$  are methyl and a preferred alkyne is 2-methyl-3-butyn-2-ol. In a second embodiment, the alkyne is 15 an alkyne-silane, for example (trimethylsilyl)acetylene. Such suitable alkynes are depicted below.



Step (i) of the process of the present invention requires reaction of the alkyne with a Lewis acidic metal salt to form a metal-alkyne complex. The Lewis acidic metal is preferably zinc, iridium(I) or indium and the salt is preferably a metal triflate (i.e. a metal 20 trifluoromethanesulphonate). Most preferably the Lewis acidic metal salt is zinc triflate. The Lewis acid may if desired be supported on an insoluble support material, for example a polymeric support or an inorganic support such as silica, a metal oxide, zeolite or an aluminosilicate to facilitate catalyst recovery and re-use.

25 A cyclic amine base is present during the first step of the process of the present invention. By 'cyclic amine base' we mean a basic amine wherein at least one nitrogen atom forms part of a ring structure. In particular we have found that the tertiary alkyl amine catalysts used heretofore such as triethylamine when used in the process of the present invention do not provide the desired hydroxyalkyne products reproducibly or in high yield (e.g. <10%). 30 Preferably the cyclic amine base is selected from the group comprising 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo-[4.3.0]non-5-ene (DBN) and 1,4-diazabicyclo[2.2.2]octane (DBN), particularly DBU.

The process further requires the presence, during step (i), of an alkanolamine ligand. Preferably the amine group on the alkanolamine is a tertiary amine group (i.e.  $NR'_3$  where  $R'$  = alkyl or cycloalkyl) and the hydroxyl group is in a  $\beta$ -position to it. Also, preferably either a chiral (+) or (-) alkanolamine ligand is used that interacts with the metal-alkyne complex to direct the 5 chirality of the hydroxyalkyne reaction product. The terms "(+)" or "(-)" here refer to the effect of the molecular structure on the direction of rotation of plane polarized light. Hence, for example a single enantiomer (+)-ligand may provide a reaction product with a greater number of (R)-chiral centres and a (-)-ligand likewise may provide a product with a greater number of (S)-chiral centres. Hence, the alkanolamine ligand is most preferably a chiral  $\beta$ -alkanolamine 10 having a tertiary amine group. Suitable alkanolamine ligands are depicted below.



Most preferably the alkanolamine ligand is (+)- or (-)-N-alkyl- or aryl-ephedrine, especially (+)- or (-)-N-methylephedrine. In the process of the present invention (+)-N-methylephedrine produces predominantly (R)-chiral centres whilst (-)-N-methylephedrine produces 15 predominantly (S)-chiral centres.

The product of process of the present invention is a hydroxyalkyne having a hydroxymethyl group bound to the alkyne [e.g.  $R^1R^2C(OH)C\equiv CH(OH)CH_3$ ]. Preferably the product is a chiral hydroxyalkyne, the chiral centre being the carbon atom to which the hydroxyl and methyl 20 groups derived from the acetaldehyde molecule are bound. Depending on whether the (+) or (-) alkanolamine ligand was used the product hydroxyalkyne may have predominantly an (R-) or (S-) configuration at the chiral centre. Furthermore, if the alkyne starting material was itself chiral and possessed predominantly an (R)- or (S)-chiral centre (opposed to a racemic mixture), the product hydroxyalkyne may be homochiral, i.e., (R,R) or (S,S) or have one (R) 25 and one (S) centre. Herein the term "chiral" refers to a molecular structure that does not have an improper rotation axis ( $S_n$ ), i.e., it belongs to point group  $C_n$  or  $D_n$ . Such molecules are thus chiral with respect to an axis, plane or centre of asymmetry. The term "homochiral" refers to a structure having two, or more, chiral centres having the same conformation.

30 Step (i) of the process of the present invention is performed in the absence of an additional solvent. By 'absence of an additional solvent' we mean that the reaction is performed between

the terminal alkyne, Lewis acidic metal salt, cyclic amine base and alkanolamine ligand substantially in the absence of a further solubilising substance. The reaction conditions employed should therefore be such that the alkyne is able to react with the Lewis acidic metal salt, and under reaction conditions the alkyne should be in the liquid phase. To facilitate mixing, the terminal alkyne is preferably used in excess. I.e. the alkyne in excess acts as the medium for its reaction with the Lewis acidic metal salt. Step (ii) of the process of the present invention requires that the acetaldehyde is diluted with a solvent. The acetaldehyde is preferably added slowly and/or in high dilution to reduce the amount of self-condensation. The solvent may be a hydrocarbon, an aromatic hydrocarbon, an ether, an alcohol or a chlorinated hydrocarbon. Examples of suitable solvents include dichloromethane, diethylether, tetrahydrofuran, ethanol, iso-propanol, heptanes, toluene and xylene. The preferred solvent for acetaldehyde is toluene. To avoid excessive amounts of solvent, the acetaldehyde concentration is preferably greater than 0.1 moles/litre. To avoid acetaldehyde self-condensation the maximum concentration is preferably less than 2 mole/litre, more preferably less than 1 mole/litre and most preferably less than 0.5 mole/litre.


Step (i) of the process of the present invention is preferably performed under mild conditions. For example, the reactions may be performed at temperatures ranging from -20 to 80°C over a period of 0.5 to 24 hours. Preferably the reaction is performed at 15-60°C over a period of 1 to 20 10 hours. Step (ii) of the process of the present invention should be carried out under lower temperature conditions, e.g. -20 to 30°C over a period of 0.5 to 24 hours due to the low boiling point of acetaldehyde. The addition should be controlled to minimise self-condensation of the acetaldehyde. Preferably the reaction is performed at -20 to 25°C over a period of 3 to 10 hours.

25 The Lewis acidic metal salt, terminal alkyne, cyclic amine base, alkanolamine ligand and acetaldehyde molar ratios can be varied substantially, leading to an increase in the yields and enantioselectivities. The terminal alkyne may be preferably present in large molar excess (e.g. >10 moles per mole of acetaldehyde) and acts as the reaction medium for step (i) of the process. Otherwise the acetaldehyde and terminal alkyne (in the form of the metal-alkyne complex) may be combined in the range 1.3:1 to 1:1.3 moles (alkyne : acetaldehyde). The Lewis acidic metal salt may be added at a molar ratio in the range 0.05:1 to 3:1, preferably 1:1 to 2:1, particularly 1.5:1 (Lewis acidic metal salt : acetaldehyde). The cyclic amine base may be added at a molar ratio in the range of 0.3:1 to 3:1, preferably 1:1 to 2:1, especially 1.6:1 (cyclic amine base : acetaldehyde). The alkanolamine ligand may be added at a molar ratio in the range 0.05:1 to 3:1, preferably 1:1 to 2:1, particularly 1.6:1 (alkanolamine ligand : acetaldehyde).

The reaction product of the process of the present invention may be recovered from the reaction mixture using work-up procedures known to those skilled in the art. For example, the reaction may be quenched by addition of saturated aqueous ammonium chloride ( $\text{NH}_4\text{Cl}$ ) solution and the resulting aqueous layer extracted with an ether. The ether may be washed with saturated aqueous sodium chloride ( $\text{NaCl}$ ) solution and dried (e.g. over anhydrous magnesium sulphate ( $\text{MgSO}_4$ )), filtered and concentrated *in vacuo*. Yield and enantioselectivity may be determined using standard analytical methods, e.g. GC analysis.

5 In one preferred embodiment, we have found that the combination of slow addition of acetaldehyde to the metal-alkyne complex in excess alkyne, wherein the metal-alkyne complex is formed in the presence of DBU and (+) N-methylephedrine affords an acetaldehyde-derived hydroxyalkyne product in considerably improved yields.

10 The acetaldehyde-derived hydroxyalkyne product may if desired be subjected to a thermal fragmentation reaction (iii) to remove the group attached to the alkyne to provide a hydroxyalkyne product for example using 2-methyl-3-butyn-2-ol (I) as follows;



15 The thermal fragmentation reaction (iii) may be performed using the methods described in Carreira et al, *Organic Letters*, 2000, 2(26), 4233-4236, and generally involves heating the hydroxyalkyne product in the presence of an inorganic base, e.g. potassium carbonate and optionally a crown ether, e.g 18-C-6. A preferred product of step (iii) is 2-hydroxybut-3-yne (III). The resulting thermally fragmented hydroxyalkyne is consequently itself a terminal alkyne and may, if desired, be further reacted with a second aldehyde molecule and hydrogenated according to the process of WO 02/094741 to yield an unsymmetrical 1,4-diol or may be reacted with a further equivalent of acetaldehyde according to the method of the present invention to yield hexyne-2,5-diol,  $[\text{CH}_3\text{C}(\text{OH})\text{C}\equiv\text{CC}(\text{OH})\text{CH}_3]$ . If desired the hexyne-2,5-diol may be hydrogenated using methods known in the art to hexene-2,5-diol or hexane-2,5-diol.

20 Where the product of the process is, or is used to prepare a thermally stable diol, the diols may be used in the synthesis of a range of cyclic phosphines using methods known to those skilled in the art. If chiral diols are chosen, the resulting chiral cyclic phosphines may be used for the

construction of asymmetric catalysts useful for example, for asymmetric hydrogenation (see for example Burk et al, *J. Am. Chem. Soc.*, 1995, 117, 4423-4424, Scheme 1)

The invention is further illustrated by reference to the following examples.

5

All reactions were performed using oven-dried glassware under an atmosphere of dry nitrogen. Toluene was distilled and dried before use. Reagents were purchased from Fluka or Aldrich chemical companies, and used without further purification except acetaldehyde which was distilled before use.

10

Example 1: Comparative Example

Using a general procedure for the nucleophilic addition of terminal alkynes to aldehydes in solvent as proposed by Frantz, D. E.; Fässler, R.; Carreira, E. M. *J. A. Chem. Soc.* 2000, 122, 1806-1807. Example 1.1: A 10 mL flask was charged with zinc triflate (200 mg, 0.550 mmol, 1.1 eq) and (+)-N-methylephedrine (108 mg, 0.602 mmol, 1.2 eq) and purged with nitrogen for 15 min. To the flask was added toluene (1.5 mL) and triethylamine (61 mg, 0.602 mmol, 1.2 eq). The resulting mixture was stirred at 23°C for 2 hours before the alkyne, 2-methyl-3-butyn-2-ol (I) (0.600 mmol, 1.2 eq) was added by syringe in one portion. After 15 min of stirring acetaldehyde (0.5 mmol, 1.0 eq) was added in one portion by syringe. The reaction was allowed to stir overnight and then quenched by the addition of saturated aqueous ammonium chloride ( $\text{NH}_4\text{Cl}$ ) solution (3 mL). The reaction mixture was poured into a separating funnel containing diethyl ether (10 mL). The layers were separated and the aqueous layer was extracted with diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous  $\text{MgSO}_4$  and concentrated in vacuum.

25

The products were analysed using gas chromatography (GC). GC method: Lipodex-E column, 95°C, 55 psi, retention time: 16.6 min (minor isomer), 17.5 min (major isomer).

30

The above experiment was repeated (Examples 1.2 – 1.8), changing solvent for step (i), amine base and reaction temperature.

The conditions and results for Examples 1.1 – 1.9 are depicted in the following Table.

Example	Solvent	Zn(OTf) <sub>2</sub> eq <sup>2</sup>	Base	Base eq <sup>2</sup>	Alkanol- amine ligand	Ligand eq <sup>2</sup>	Temp.	Yield %	ee <sup>4</sup> %
1.1	Toluene	1.1	Et <sub>3</sub> N	1.2	nme <sup>3</sup>	1.2	23	<20	60
1.2	Toluene	1.1	Et <sub>3</sub> N	1.2	nme	1.2	30	0	-
1.3	Toluene	1.1	Et <sub>3</sub> N	1.2	nme	1.2	40	0	-
1.4	CH <sub>2</sub> Cl <sub>2</sub>	1.1	Et <sub>3</sub> N	1.2	nme	1.2	20	0	-
1.5	Toluene	1.1	iPr <sub>2</sub> EtN	1.2	nme	1.2	20	<20	50
1.6	Toluene	1.1	pyridine	1.2	nme	1.2	20	0	-
1.7	Toluene	1.1	DBU	1.2	nme	1.2	20	<20	60
1.8	Toluene <sup>1</sup>	1.1	DBU	1.2	nme	1.2	20	0	-
1.9	iPrOH	1.5	DBU	1.6	nme	1.6	20	0	-

1. Solvent increased by a factor of 20 (volume).
2. eq = equivalents, i.e. moles per mole acetaldehyde
3. nme = (+)-N-methylphedrine.
4. ee% = enantiomeric excess

In all cases the yield of (R)-2-methylhex-3-yne-2,5-diol (II) was always less than 20% (based on acetaldehyde). Changing the solvent, base and relative amounts of zinc triflate, base and alkanolamine ligand did not increase the yield.

Example 2: Reaction of acetaldehyde with 2-methyl-3-butyn-2-ol

Step (i): Zinc triflate (10.9 g, 30 mmol, 1.5 eq), (+)-N-methylmorpholine (5.7 g, 32 mmol, 1.6 eq), DBU (4.8 mL, 32 mmol, 1.6 eq) and 2-hydroxy-2-methyl-3-butyne (Alkyne 1, 80 mL) were stirred at room temperature for 2 h. Step (ii): a solution of acetaldehyde (1.13 mL, 20 mmol) in toluene (50 mL) was then slowly added over a 4 hour period. After stirring overnight at room temperature, the reaction was quenched by addition of sat. aq. NH<sub>4</sub>Cl (50 mL). The aqueous layer was extracted with methyl-tertiary-butyl ether (MTBE) (2 x 50 mL). The combined organic layers were washed with sat. aq. NaCl (100 mL), dried (MgSO<sub>4</sub>), filtered and concentrated *in vacuo*. Purification of the crude material by filtration through a plug of silica afforded 2.25 g of (II) as a yellow oil in 87% yield and 67% ee as determined by GC analysis. GC method: Lipodex-E column, 95 °C, 55 psi, retention time: 16.6 min (minor isomer), 17.5 min (major isomer).

The above experiment was repeated whereby the second step (ii) was carried out at 0°C or -10°C. The yields were 50% or greater and the enantioselectivities were also 67%.

5 This example demonstrates the surprising effect that by omitting the solvent for metal-alkyne complex formation the process of the present invention provides acetaldehyde-derived hydroxyalkynes in high yield.

Example 3: thermal fragmentation of (II) to yield 2-hydroxybut-3-yne

10 The isolated reaction product from Example 2, (*R*)-2-Methylhex-3-yne-2,5-diol, was mixed with 1.5 equivalents of K<sub>2</sub>CO<sub>3</sub> in toluene. The reaction flask was then placed in the Kugelrohr oven and heated at 120 °C under vacuum. As the thermal fragmentation reaction takes place, (*R*)-(+)-3-butyn-2-ol was gradually distilled off the reaction mixture and collected in 40-60% yield.

Claims

1. A process for performing a coupling reaction between acetaldehyde and a terminal alkyne to yield a hydroxyalkyne comprising the steps of:
  - (i) Reacting in the absence of a solvent, a terminal alkyne with a Lewis acidic metal salt in the presence of a alkanolamine ligand and a cyclic amine base to form a metal-alkyne complex, and
  - (ii) adding a solution of acetaldehyde to the metal-alkyne complex and allowing the mixture to react.
2. A process according to claim 1 wherein the terminal alkyne is of general formula  $R^1R^2C(OH)C\equiv CH$  in which  $R^1$  and  $R^2$  may be the same or different and are selected from the group comprising methyl, ethyl and propyl.
3. A process according to claim 1 or claim 2 wherein the Lewis acidic metal salt is zinc triflate.
4. A process according to any one of claims 1 to 3 wherein the alkanolamine ligand is a chiral  $\beta$ -alkanolamine having a tertiary amine group.
5. A process according to any one of claims 1 to 4 wherein the alkanolamine ligand is (+)- or (-)-N-methylephedrine.
6. A process according to any one of claims 1 to 5 wherein the cyclic amine base is selected from the group comprising 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene and 1,4-diazabicyclo[2.2.2]octane.
7. A process according to any one of claims 1 to 5 wherein the acetaldehyde concentration is between 0.1 and 2 moles/litre.
8. A process according to any one of claims 1 to 7 wherein step (ii) is performed at -20 to 25°C over a period of 3 to 10 hours.
9. A process according to any one of claims 1 to 8 wherein the molar ratio of the Lewis acidic metal salt : acetaldehyde is 1.5:1, the molar ratio of cyclic amine base: acetaldehyde is 1.6:1 and the molar ratio of alkanolamine ligand to acetaldehyde is 1.6:1.
10. A process according to any one of claims 2 to 9 wherein the reaction product of the coupling reaction is subjected to a thermal fragmentation reaction to yield a terminal alkyne.

Abstract

A process for performing a coupling reaction between acetaldehyde and a terminal alkyne to yield a hydroxyalkyne is described comprising the steps of;

- iv) Reacting in the absence of a solvent, a terminal alkyne with a Lewis acidic metal salt in the presence of a alkanolamine ligand and a cyclic amine base to form a metal-alkyne complex, and
- v) adding a solution of acetaldehyde to the metal-alkyne complex and allowing the mixture to react.

**PCT/GB2004/001639**

